Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience

Published:2021-12 Issue: Volume:26 Page:100561
ISSN:1665-2681
Container-title:Annals of Hepatology
language:en
Short-container-title:Annals of Hepatology

Author:

da Silva Joana Alves,Falcão Daniela,Cardoso Cláudia,Pires Ana Luísa,Araújo António,Castro-Poças Fernando

Funder

Centro Hospitalar Universitário do Porto EPE

Publisher

Elsevier BV

Subject

Hepatology,General Medicine

Reference35 articles.

1. Immune-related adverse events associated with immune checkpoint blockade;Postow;N Engl J Med,2018

2. Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: a multicenter retrospective study;Okada;Clin Ther,2019

3. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management;Samaan;Nat Ver Gastroenterol Hepatol,2018

4. Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma;Larkin;N Engl J Med,2015

5. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer;Osorio;Ann Oncol,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatobiliary complications of immune checkpoint inhibitors in cancer;Exploration of Targeted Anti-tumor Therapy;2024-07-26

2. New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury;International Immunopharmacology;2024-04

3. Key Determinants of Immune-Mediated Adverse Reactions to Oncology Drugs;Cancers;2023-11-28

4. Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma;Hepatology Research;2023-10-06

5. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System;Clinical Therapeutics;2023-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3